3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
5
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
durvalumab
4
Cisplatin
4
pembrolizumab
3
abemaciclib
3
Pemetrexed
3
Fulvestrant
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ribociclib
2
palbociclib
2
Nivolumab
2
Letrozole
2
Gemcitabine
2
Bevacizumab
2
Anastrozole
2
selpercatinib
1
selinexor
1
repotrectinib
1
relatlimab
1
relacorilant
1
pralsetinib
1
olaparib
1
gallium 68 PSMA-11
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
darolutamide
1
ceralasertib
1
cemiplimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Imlunestrant
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled